Corporate Partnerships, Affiliations, Collaborations

CHIBI and its faculty strive to impact discovery and patient care through all suitable channels including by developing industrial partnerships, collaborations, and consulting relationships.

Geisinger Health System: Geisinger Health System is developing a partnership with NYU in the areas of healthcare delivery; comparative effectiveness research; genetic epidemiology, genomics and biomarker research; clinical molecular diagnostics and theranostics; and behavior change research. CHIBI is an important component of this exciting initiative bringing to the collaborative world-class expertise in predictive modeling, causal discovery, biomarker discovery, multi-modal data analytics, and all types of upstream and downstream high throughput assay bioinformatics.

Sanctis: CHIBI has secured from Sanctis LLC, a company specializing in the computational data analytics of molecular profiles and personalized medicine the non-exclusive license to use all of Sanctis’s IP portfolio for non-commercial applications, such as research grants, as well as application of Sanctis technology for internal NYU non-commercial uses. Currently Sanctis technology powers a large part of CHIBI’s research projects including several CTSA informatics aims.

ClopiNet: CHIBI researchers have long-standing working scientific relationship with ClopiNet through its founder Dr. Isabelle Guyon. This relationship spans new methods development, the international Causal and Predictive Challenge, jointly sought grants, and publications.

Pfizer: CHIBI faculty Dr. Michael Cantor is Health Informatics Director at Pfizer. His work focuses on the secondary use of clinical data, personalized medicine, and automated methods for pharmacovigilance. At Pfizer, he is leading the PEER (Pfizer Externally Enabled Research) initiative, which aims to partner with academic medical centers to perform observational studies using data from electronic medical record (EMR) systems. He also helped lead Pfizer’s efforts with the e-Health Initiative’s Connecting Communities for Drug Safety, a partnership between academia and the pharmaceutical industry exploring the use of EMRs for pharmacovigilance. He is a member of Pfizer’s Personalized Medicine SMART team, and helped organize Pfizer’s Personalized Medicine symposium.

Merck: CHIBI faculty worked recently with Merck molecular profile department researchers to analyze atherosclerosis progression and regression microarray data from Ed Fisher’s lab. Several manuscripts are in preparation.

To transform the way research is carried out at New York University (NYU) and enhance the quality and productivity of the research effort, NYU and the New York City Health and Hospitals Corporation (HHC) established the NYU-HHC Clinical and Translational Science Institute (CTSI). The CTSI aims to increase collaboration among clinical, translational and basic scientists across NYU to better determine the relevance and applicability of scientific advances to clinical problems. It also strives to provide leadership, infrastructure and resources to support novel science and the rapid, efficient and safe application of scientific discoveries to the community. A third aim is to support education, training and development of researchers who can conduct the investigations necessary to bring scientific advances to the public. Finally, the CTSI works to enhance the ties between NYU researchers and the community in order to more rapidly identify health problems, investigate their scientific basis, apply the knowledge gained, promote use of new developments and evidence-based medicine by the community, and reduce health care disparities.

NYC HCC: The CHIBI leads and implements the Informatics Core for the CTSI, facilitating thus the goals of this important institute though the participation of several of CHIBI faculty and staff. In addition, CHIBI faculty Dr. John Chelico is an Assistant Chief Medical Information Officer (CMIO) at New York City Health and Hospitals Corporation